Safety, Pharmacokinetics, and Predicted Lung Concentration of a Novel SARS-CoV2 Mpro Inhibitor in Healthy Volunteers

Hu et al., International Conference on Emerging Infectious Diseases, August 2022, Aug 2022
Phase 1 RCT 120 healthy volunteers (80 US, 40 China) showing safety and tolerability of FB2001 (bofutrelvir).
Important missing comments or errors? Let us know.
Hu et al., 8 Aug 2022, peer-reviewed, 10 authors.
Bofutrelvir (FB2001) is an intravenously administered small molecule covalent inhibitor of the SARS-CoV-2 main protease (Mpro/3CLpro).
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0